ReviewClinics (Sao Paulo, Brazil)2014
Gonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech.
Review in Clinics (Sao Paulo, Brazil), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 110 citations in OpenAlex.
- Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles.The Cochrane database of systematic reviews · 2016Pooled it
- Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART).Reproductive biology and endocrinology : RB&E · 2016Trial
- Microarray patches as a potential alternative to injectable fertility medications: a qualitative study of patients' and healthcare professionals' perceptions.International journal of clinical pharmacy · 2026Article
- Empty Follicle Syndrome: Current Therapeutic Approaches and the Role of Triggering Agents in Assisted Reproductive Technology.Medical sciences (Basel, Switzerland) · 2026Review
- Comparing clinical outcomes of rFSH versus rFSH+HP-hMG in women undergoing in vitro fertilization-embryo transfer in real‑world practice: a retrospective study.Scientific reports · 2026Article
- Disulfide Bond Mapping of Follitropin Delta, a Recombinant Follicle Stimulating Hormone (rFSH), by X-Ray Crystallography.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Investigation of the effects of recombinant and urinary FSH used for ovulation induction on pregnancy results in an experimental animal model in terms of endometrial receptivity markers.BMC pregnancy and childbirth · 2026Article
- Quantitative determination of trace principal components with high specific activity in menotropins.Frontiers in bioengineering and biotechnology · 2026Article
- The role of luteinizing hormone in the management of female infertility: A French Delphi consensus.Journal of assisted reproduction and genetics · 2025Article
- Pituitary extract supplementation enhances follicular survival and gonadotropin receptor expression in vitrified ovarian tissue of Aceh cattle, Indonesia.Veterinary world · 2025Article
- Monoclonal antibody potentiating gonadotropin activity in vitro and in vivo in male and female rats and in ewes.Reproduction (Cambridge, England) · 2025Article
- Comparison of efficacy, safety, and economy of recombinant and urinary follicle-stimulating hormone in women with a predicted normal response undergoing assisted reproductive technology.Journal of ovarian research · 2025Article
- Prospective Assessment of Gonadotropin Therapy and Its Outcome in Nonobstructive Azoospermic Patients.Cureus · 2025Article
- Introduction: luteinizing hormone for life's journey.Reproductive biology and endocrinology : RB&E · 2025Article
- The role of luteinizing hormone activity in spermatogenesis: from physiology to clinical practice.Reproductive biology and endocrinology : RB&E · 2025Review
- Affordable mRNA Novel Proteins, Recombinant Protein Conversions, and Biosimilars-Advice to Developers and Regulatory Agencies.Biomedicines · 2025Review
- Article
- Effect of follicle-stimulating hormone dose on the risk of being classified as suboptimal responders according to the POSEIDON criteria.Journal of assisted reproduction and genetics · 2024Article
- Advancing Therapeutic and Vaccine Proteins: Switching from Recombinant to Ribosomal Delivery-A Humanitarian Cause.International journal of molecular sciences · 2024Review
- Severe ovarian hyperstimulation syndrome following sole gonadotropin-releasing hormone (GnRH) agonist trigger: a case series and literature review.Archives of gynecology and obstetrics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gonadotropin therapy plays an integral role in ovarian stimulation for infertility treatments. Efforts have been made over the last century to improve gonadotropin preparations. Undoubtedly, current gonadotropins have better quality and safety profiles as well as clinical efficacy than earlier ones. A major achievement has been introducing recombinant technology in the manufacturing processes for follicle-stimulating hormone, luteinizing hormone, and human chorionic gonadotropin. Recombinant gonadotropins are purer than urine-derived gonadotropins, and incorporating vial filling by mass virtually eliminated batch-to-batch variations and enabled accurate dosing. Recombinant and fill-by-mass technologies have been the driving forces for launching of prefilled pen devices for more patient-friendly ovarian stimulation. The most recent developments include the fixed combination of follitropin alfa + lutropin alfa, long-acting FSH gonadotropin, and a new family of prefilled pen injector devices for administration of recombinant gonadotropins. The next step would be the production of orally bioactive molecules with selective follicle-stimulating hormone and luteinizing hormone activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.